The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating tumor cells (CTCs) and TOP2A gene expression are key biomarkers for predicting breast cancer (BC) recurrence and metastasis. Positive hormone receptor expression in BC patients is associated with favorable progression-free survival (PFS).
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Advanced stage breast cancer (BC) is associated with poor patient outcomes due to high recurrence and metastasis rates.
- Identifying reliable biomarkers for prognosis prediction in BC is crucial for improving patient management.
- This study investigates the prognostic value of circulating tumor cells (CTCs) in BC patients.
Purpose Of The Study
- To evaluate the relationship between circulating tumor cells (CTCs) and clinical outcomes in breast cancer (BC) patients.
- To identify critical biomarkers for predicting recurrence and metastasis in BC.
- To assess the impact of CTC subtypes and TOP2A gene expression on patient prognosis.
Main Methods
- Fifty female BC patients were analyzed using CanPatrol™ technology and RNA-ISH to detect CTC subtypes (eCTCs, MCTCs, HCTCs) and TOP2A gene expression.
- Hormone receptor (ER, PR, HER-2) status was determined by immunohistochemistry (IHC).
- COX regression and Kaplan-Meier survival analysis were employed to identify risk factors and assess progression-free survival (PFS).
Main Results
- High total CTCs (TCTCs) and TOP2A expression were observed in patients with larger tumor size and advanced TNM stages.
- TOP2A expression in TCTCs, ER+, HER-2+, and TNM stage were identified as critical risk factors for recurrence and metastasis.
- Patients with high TCTCs, hybrid CTCs (HCTCs), and positive TOP2A expression showed significantly different PFS compared to those with lower levels.
Conclusions
- Elevated TCTC counts, HCTCs, and positive TOP2A gene expression on CTCs serve as critical biomarkers for predicting BC patient outcomes.
- Positive hormone receptor expression (ER+, PR+, HER-2+) in BC patients is associated with significantly longer progression-free survival (PFS).
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...